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Abstract
 
M11L, an antiapoptotic protein essential for the virulence of the myxoma poxvirus, is targeted
to mitochondria and prevents the loss of mitochondrial membrane potential that accompanies
cell death. In this study we show, using a cross-linking approach, that M11L physically associ-
ates with the mitochondrial peripheral benzodiazepine receptor (PBR) component of the per-
meability transition (PT) pore. Close association of M11L and the PBR is also indicated by
fluorescence resonance energy transfer (FRET) analysis. Stable expression of M11L prevents
the release of mitochondrial cytochrome c induced by staurosporine or protoporphyrin IX
(PPIX), a ligand of the PBR. Transiently expressed M11L also prevents mitochondrial mem-
brane potential loss induced by PPIX, or induced by staurosporine in combination with
PK11195, another ligand of the PBR. Myxoma virus infection and the associated expression of
early proteins, including M11L, protects cells from staurosporine- and Fas-mediated mitochon-
drial membrane potential loss and this effect is augmented by the presence of PBR. We con-
clude that M11L regulates the mitochondrial permeability transition pore complex, most likely
by direct modulation of the PBR.
Key words: apoptosis • mitochondria • PK11195 • protoporphyrin IX • 
 
Poxviridae
 
Introduction
 
Apoptotic cell death is central to many aspects of the sur-
vival of multicellular organisms (1). For example, initiation
of a cellular suicide program after infection serves as an effec-
tive means of curtailing viral propagation and provides an
early host defense against infection. However, numerous
viruses have developed effective strategies to circumvent
apoptosis in order to extend the life of the infected cell to
 
their advantage
 
 
 
(2, 3). One such virus, with diverse anti-
apoptotic strategies, is myxoma virus (4).
Myxoma virus is a poxvirus of rabbits and the causative
agent of the lethal disease, myxomatosis. This virus encodes
M11L, a key virulence factor that inhibits apoptosis of in-
fected cells, particularly monocytes (5, 6). The dramatic
contribution of M11L to viral pathogenesis was recognized
during characterization of an 
 
M11L
 
 knockout virus, which
cannot produce M11L protein. Infection of rabbits with
the 
 
M11L
 
 knockout virus resulted in highly attenuated dis-
ease symptoms and full recovery. In contrast, wild-type vi-
rus infection resulted in rapid and complete mortality (7).
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M11L is also antiapoptotic when expressed autonomously
from other viral proteins, is targeted to the cytoplasmic sur-
face of the outer mitochondrial membrane and prevents
loss of mitochondrial membrane potential (
 
  
 
m
 
)
 
* 
 
in re-
sponse to staurosporine-induced apoptosis (6). M11L is
therefore functionally implicated in modulating the mito-
chondrial cell death control point.
Mitochondria play a key role in many apoptotic cascades
and apoptotic cell death is frequently accompanied by two
marked mitochondrial changes that can occur indepen-
dently, but frequently occur concurrently (8–11). One of
these changes is the release into the cytosol of proteins that
are normally retained in the intermembrane space between
the inner and outer mitochondrial membranes. Proteins in-
volved in this redistribution include several apoptotic effec-
tors and cofactors that transduce apoptotic signals upon en-
tering the cytoplasm. The other notable mitochondrial
change is the abrupt loss of the electrochemical potential
(
 
  
 
m
 
) normally maintained across the inner membrane.
Either one of these two mitochondrial events could presage
commitment to cell death and consequently, the exact mi-
tochondrial perturbation required to ensure the death of a
cell remains controversial.
The loss of 
 
  
 
m
 
 occurs as a result of the sudden opening
of a mitochondrial megachannel referred to as the perme-
ability transition (PT) pore. The PT pore is thought to
consist of three core protein subunits: the voltage-depen-
dent anion carrier (VDAC) that resides in the outer mito-
chondrial membrane, the adenine nucleotide transporter
(ANT) in the inner membrane, and cyclophilin D that is
associated with the matrix surface of the ANT (12). Pro-
and antiapoptotic members of the Bcl-2 family of proteins
are reported to physically associate with the ANT and
VDAC subunits and to regulate the PT pore (13, 14).
However, the molecular mechanisms underlying the effects
of the Bcl-2 proteins are presently unclear. Interestingly,
several viral apoptotic modulators also regulate the PT pore
by direct interaction with its components (15, 16). In par-
ticular, vMIA of cytomegalovirus (17) and Vpr encoded by
HIV (18, 19), associate with the ANT, while HBx, en-
coded by hepatitis B virus, binds to VDAC (20). The PT
pore incorporates several accessory proteins including cre-
atine kinase, Hexokinase II, and the peripheral benzodiaz-
epine receptor (PBR; references 8, 12, 21, and 22). The
role of these proteins in apoptosis modulation remains
poorly understood.
The PBR is an 18-kD integral membrane protein which
resides in the outer mitochondrial membrane and copuri-
fies with the VDAC and ANT components of the PT pore
 
(23). PBR protein is concentrated in contact sites between
the inner and outer mitochondrial membranes (24), as are
PT pore assemblies and Bcl–2 (25). Microscopy has re-
vealed that the PBR is localized on the cytoplasmic surface
of mitochondria and is present in pore-like clusters of 4–6
molecules. Each cluster is predicted to be associated with
one VDAC molecule (26).
The PBR was first characterized as a benzodiazepine-
interacting protein present in certain peripheral tissues (27)
and has since been shown to have a wide tissue distribu-
tion, being abundant in the adrenals, kidney, heart, and re-
productive tract, and also present in nonneuronal brain
tissue (21, 22). Within leukocyte subsets, the highest con-
centrations of the PBR are found in monocytes and poly-
morphonuclear cells (28, 29). The PBR shows highest
affinity for the isoquinoline carboxamide analogue, 1-(2-
chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquino-
linecarboxamide (PK11195) and the diazepine 4
 
 
 
-chlorodi-
azepam (Ro 5–4864; references 21 and 22). Porphyrins are
the major endogenous ligands of the PBR, with the heme
precursor, protoporphyrin IX (PPIX) having the strongest
binding interaction (30). The pharmacological properties
and tissue distribution of the PBR distinguishes this recep-
tor from the ‘central type’ benzodiazepine receptor that is
present on the surface of cells of the central nervous system
and preferentially binds the theraputic diazepines (21).
Numerous physiological functions have been proposed
for the PBR, including roles in the regulation of cellular
growth and proliferation, heme biosynthesis, cholesterol
transport, and steroidogenesis (21, 22) in addition to an
ability to potentiate inflammation (31, 32). Two lines of
evidence also implicate the PBR in apoptosis modulation.
First, elevated levels of PBR expression confer protection
against apoptosis. Specifically, in hematopoeitic cells, PBR
overexpression correlates with resistance to H
 
2
 
O
 
2
 
- and
UV-mediated cell death (28, 33). Interestingly, enforced
expression of PBR also protects neonatal mice from the
otherwise lethal effects of a neurovirulent, proapoptotic
strain of Sindbis virus (34). Second, PBR ligands can in-
duce apoptosis, presumably by binding to the PBR and in-
terfering with the function of the PT pore. In particular,
exogenous addition of PPIX (35) or PK11195 (36–39) to
certain cell types, or addition of PPIX or PK11195 in com-
bination with proapoptotic agents to other cell types (40–
46) has been shown to potentiate 
 
  
 
m
 
 loss and cell death.
Also, PPIX mediates apoptotic death of cells in culture and
within brain tumors during photodynamic therapy (47,
48). Notably, Bcl-2 cannot prevent the proapoptotic effects
of PK11195 (37, 43–45) or PPIX (35). Therefore, Bcl-2
most likely does not prevent apoptosis by physical interac-
tion with the PBR subunit of the PT pore.
Despite being implicated in apoptotic events, clear evi-
dence to show involvement of the PBR in apoptosis mod-
ulation has remained elusive. In this study we show that
M11L, an anti-apoptotic, mitochondria-localized protein,
physically associates with the PBR subunit of the PT pore
and counteracts the proapoptotic effects of PBR ligands.
In this way, M11L forestalls transduction of cell death sig-
 
*
 
Abbreviations used in this paper:
 
 
 
  
 
m
 
, mitochondrial membrane potential;
ANT, adenine nucleotide transporter; DSS, disuccinimidyl suberate; DSP,
dithiobis(succinimidylpropionate); EGFP, enhanced green fluorescent pro-
tein; EYFP, enhanced yellow fluorescent protein; FRET, fluorescence res-
onance energy transfer; MOI, multiplicity of infection; PBR, peripheral
benzodiazepine receptor; PK11195, 1-(2-chlorophenyl)-N-methyl-N-(1-
methylpropyl)-3-isoquinolinecarboxamide; PPIX, protoporphyrin IX; PT,
permeability transition; STS, staurosporine; TMRE, ethyl ester of tetra-
methyl rhodamine; VDAC, voltage dependent anion carrier. 
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nals at the mitochondrial control point. This is the first re-
port of an apoptotic modulator binding directly to the
PBR, thereby identifying a direct role for this PT pore
subunit in apoptosis.
 
Materials and Methods
 
Cells and Culture Conditions.
 
The Cos-7 monkey kidney, HeLa
human cervical carcinoma, THP-1 human monocyte, and Jurkat
T lymphocyte (clone E6) cell lines were obtained from American
Type Culture Collection. Cos-7 cells were cultured in DMEM
and the other cell lines were cultured in RPMI medium. All me-
dia were supplemented with 10% FBS, 200 U/ml penicillin, and
200 
 
 
 
g/ml streptomycin. THP-1 medium also contained 0.1
mM 2-mercaptoethanol. BGMK monkey kidney cells (7) were
grown in DMEM supplemented with 10% newborn calf serum,
200 U/ml penicillin, and 200 
 
 
 
g/ml streptomycin. The develop-
ment of Rat2puro and Rat2M11L cell lines has been described
previously (6) and these cells were cultured in DMEM containing
10% FBS, 200 U/ml penicillin, 200 
 
 
 
g/ml streptomycin, and 2.5
 
 
 
g/ml puromycin. Jurkat-PBR cells (reference 28; supplied by
Dr. P. Casellas, Sanofi Research, Montpellier, France) were grown
in RPMI medium containing 10% FBS, 200 U/ml penicillin, 200
 
 
 
g/ml streptomycin, 0.1 mM 2-mercaptoethanol, and 0.6 mg/ml
G418.
 
Cross-linking Assays.
 
Cos-7 cells (5 
 
 
 
 10
 
5
 
) were infected at a
multiplicity of infection (MOI) of 10 with a recombinant vac-
cinia virus that overexpresses M11L (VVM11L; reference 49) or
control vaccinia virus (VV601). Cells were then replenished with
DMEM lacking serum and containing 
 
35
 
S-labeled cysteine and
methionine at a final concentration of 0.1 mCi/ml. 12 h after in-
fection, the cells were harvested and each sample was resuspended
in 1 ml cold hypotonic 100 mM potassium phosphate buffer, pH
7.4. Samples were subjected to 35 strokes in a dounce homoge-
nizer and then divided into two aliquots. A DMSO solution of
the hydrophobic, noncleavable cross-linker disuccinimidyl suber-
ate (DSS; Pierce Chemical Co.) was added to one aliquot of each
sample to a final concentration of 1.25 mM. Samples were incu-
bated for 2 h at 4
 
 
 
C on a nutator and 0.8 ml NP-40/deoxycho-
late lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 2 mM EDTA, and 1 mM PMSF)
was added. Both monomeric and complexed M11L was immu-
noprecipitated using a polyclonal rabbit anti-M11L antibody (6)
and identified by SDS-PAGE and autoradiography. Alternatively,
THP-1 or HeLa cells were infected with VV601 or VVM11L, or
infection-permissive BGMK cells were infected at an MOI of 10
with either myxoma virus (vMyxlac) or the M11L knockout vi-
rus (vMyxM11L
 
 
 
; reference 7). Infected cell samples were sub-
jected to the cross-linking and immunprecipitation procedure de-
scribed, followed by immunoblot analysis.
 
Cross-linking and Coimmunoprecipitation Assays.
 
THP-1 cells (2 
 
 
 
10
 
6
 
) were infected at a MOI of 10 with VVM11L or VV601. 12 h
after infection, cells were subjected to hypotonic lysis, dounce
homogenization, and cross-linking as described above, except in
this case, the hydrophobic, cleavable analogue of DSS, Dithio-
bis(succinimidylpropionate) (DSP; Pierce Chemical Co.) was
used at a final concentration of 0.125 mM. Samples were divided
into duplicates and resuspended in 0.8 ml NP-40/deoxycholate
lysis buffer. Duplicate samples were then immunoprecipitated
with a polyclonal rabbit anti-M11L antibody (6) and cross-linked
complexes in one sample from each duplicate were cleaved into
their monomeric components by incubation at 65
 
 
 
C in SDS-
PAGE loading buffer containing 100 mM dithiothreitol and
 
0.2% 2-mercaptoethanol. In parallel, the same procedure was
conducted on samples immunoprecipitated with a mouse mono-
clonal anti-PBR antibody that has specificity for human PBR
(29) (supplied by Dr. P. Casellas, Sanofi Research). PBR and
M11L proteins were detected using SDS-PAGE and immuno-
blot analysis.
 
Fluorescence Resonance Energy Transfer Analysis.
 
A construct to
allow the expression of M11L appended to the C terminus of en-
hanced yellow fluorescent protein (EYFP) was generated by re-
placing the enhanced green fluorescent protein (
 
EGFP
 
) coding
sequence in the plasmid pEGFP-M11L (6) with the 
 
EYFP
 
 coding
sequence obtained from the plasmid pEYFP-C1 (CLONTECH
Laboratories, Inc.). EYFP-M11L or EYFP alone were transiently
expressed in HeLa cells by transfection of the expression plasmid
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s recommendations. Each transfection was conducted with
1 
 
 
 
g of DNA and 1 
 
 
 
l liposome reagent. Transfected cells were
cultured in Petri dishes in which the base had been replaced with
a glass coverslip (number 1; Fischer) and stained with the PBR-
specific fluorescent compound FGIN-1–27-NBD (reference 50;
Alexis Biochemicals Corp.) at a dilution of 0.7 
 
 
 
M immediately
before visualization.
An acceptor photobleaching approach (51) was used to in-
vestigate potential interactions between FGIN-1–27-NBD and
EYFP-M11L. Images were collected on a ZEISS Laser Scanning
Confocal microscope (LSM 510 META NLO) system mounted
on a ZEISS Axiovert 100M microscope using a 40
 
 
 
 lens (NA
1.3, Fluar). The Meta detector of the system allowed recording of
spectral information of the specimen with 10.7-nm bandwidth
resolution. Images were recorded using a pixel resolution of
0.15–0.2 
 
 
 
m and a pixel time of 3.2 
 
 
 
s. The gain and offset val-
ues were optimized such that no pixel saturation was observed
and the minimum values in the image were near zero. This al-
lowed the full dynamic range of the system to be used. Addition-
ally, images were acquired with a 12-bit pixel depth and an aver-
aging factor of 2 to reduce noise. Image series were recorded
using the time-lapse function of the instrument. Three images
were recorded before acceptor (EYFP) photobleaching then, two
or three more images were recorded after photobleaching in or-
der to calculate the dequenching (fluorescence resonance energy
transfer
 
 [
 
FRET] efficiency). At least two pairs of EYFP expressing
and non-EYFP expressing cells were included in each field ana-
lyzed. One EYFP-expressing and one non-EYFP expressing cell
was photobleached with the full power of the 514 nm laser line at
iterations of between 50 to 150 (mostly 100). The cells that were
not photobleached served as an internal control for each image.
The same field-of-view was also imaged with the sequential
scanning mode using the Meta detector as a bandpass filter (chan-
nel mode). For the NBD signal, a 458 nm-laser line excitation
was used and the emission signal was collected between 462 and
537 nm. For EYFP, a 514 nm excitation laser line was used and
the emission signal was collected between 526 and 719 nm. An
image was acquired before photobleaching using this setting. The
effectiveness of photobleaching was monitored by acquiring an-
other image using a higher gain for the EYFP detector channel
after photobleaching.
A common difficulty with FRET analysis is bleed through of
the donor emission spectrum into the acceptor channel. Using
the spectral imaging capability of the Meta detector, serial spectral
data ranging from 462.4 to 633.6 nm were recorded with the 458
nm laser line as an excitation source. Reference spectra for
EYFP-M11L and FGIN-1–27-NDB in living cells were recorded
with the same conditions as with the FRET image acquisitions.
Then either these reference spectra or spectra generated from re- 
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gions of interest were used with the linear-unmixing method (52)
to separate the signals. This method permitted the use of the full
range of the signal instead of using a narrow bandwidth of the
spectra. After linear unmixing, regions of interest were drawn
over four cells chosen in each field: a pair that expressed EYPF-
M11L and another pair that did not express EYPF-M11L. One
cell from each pair was photobleached and the other cell in each
pair was not subjected to photobleaching. The average pixel in-
tensity of individual cells was calculated using the LSM Software.
The data were exported to Microsoft Excel for further pro-
cessing.
Theoretically, if FRET occurs, photobleaching of the EYFP-
M11L acceptor will induce de-quenching of the donor (FGIN-
1–27-NBD) signal. The major limitation of FRET analysis in
this experimental system was caused by photobleaching of the
FGIN-1–27-NBD compound during normal image acquisition
using the 458 nm laser line (by an average amount of 7% per im-
age acquisition under the experimental conditions). To a lesser
degree, the FGIN-1–27-NBD signal was also reduced during
photobleaching of the acceptor (EYFP) with the 514 nm laser
line (
 
 
 
40% for 100 iterations). The matter was further compli-
cated by a weak excitation of EYFP molecules with the 458 nm
laser line used for FRET analysis. To circumvent these problems,
we designed the experiments so that internal controls were in-
cluded in each individual image. Parallel bleaching of another
non-EYFP-M11L expressing, FGIN-1–27-NBD-labeled cell
with the 514 nm laser line in the same image field served as an
intrinsic control for correction of these bleaching problems in the
experiments performed. Therefore, the final FRET efficiency
was calculated based on the ratio of the average intensity of
FGIN-1–27-NBD channel in the photobleached EYFP-M11L–
expressing cell versus that of FGIN-1–27-NBD channel in the
photobleached non-EYFP-M11L–expressing cell. This ap-
proach not only corrected for the photobleaching problems dis-
cussed above but it also served as an internal control for the cor-
rection of potential fluctuations of laser intensity. Additionally, in
order to compensate for intensity variations between cells, the
intensity of each cell were expressed as percentage of intensity of
the first time point of the same cell. Then, the ratios between
FRET and control cells were calculated based on these normal-
ized intensity values.
Briefly, the algorithm used for data processing was: (a) the in-
tensity in the FGIN-1–27-NBD channel at each time point was
normalized to the percentage of its intensity of the first time
point. (b) The ratios between the averaged pixel intensity of the
FGIN-1–27-NBD channel (donor molecule) in the EYFP-
M11L-expressing cell and that of the EYFP-M11L nonexpressing
cell for each time were calculated. (c) The ratios were plotted for
each time lapse point. Other pairs of EYFP and non-EYFP ex-
pressing cells in the same image field that were not photobleached
served as controls for FRET. The same image processing process
was applied to these pairs of cells and the results plotted in the
same graph for comparison purposes. We also performed control
experiments using cells labeled with the donor (FGIN-1–27-
NBD) alone, the acceptor (EYFP-M11L) alone and unlabeled
cells. In addition, we analyzed cells that were transfected with the
pEYFP-C1 vector and expressed EYFP only and were then
stained with FGIN-1–27-NBD. No dequenching phenomena
were observed in any of these controls (unpublished data).
 
Cytochrome c Translocation.
 
For the determination of cyto-
chrome c translocation into the cytoplasm, Rat2puro or
Rat2M11L cells (10
 
6
 
) were treated with 5 
 
 
 
M staurosporine
(Sigma-Aldrich) for 2, 3, or 4 h, or treated with an equivalent
 
amount of DMSO for 4 h as a solvent control. Cells were har-
vested by trypsinization and lysed at 4
 
 
 
C in 100 
 
 
 
l digitonin lysis
buffer (75 mM NaCl, 1 mM NaH
 
2
 
PO
 
4
 
, 8 mM Na
 
2
 
HPO
 
4
 
, 250
mM sucrose, and 95 
 
 
 
g/ml digitonin). Supernatant fractions
were isolated by centrifugation of samples at 15,000 
 
g
 
 and 4
 
 
 
C for
15 min and subjected to SDS-PAGE and immunoblot analysis.
Cytochrome c present in the supernatant fractions was detected
using an anti-cytochrome c antibody (BD Biosciences) and actin
levels were determined in the same samples using an anti-actin
antibody (Santa Cruz Biotechnology, Inc.). To determine the ef-
fects of PPIX on Rat2puro or Rat2M11L cells, the cells were
first permeabilized with digitonin lysis buffer, then treated with
20 
 
 
 
M PPIX or DMSO solvent alone at 37
 
 
 
C for 30 min before
analyzing the cytosolic levels of cytochrome c or actin as before.
 
Measurement of 
 
  
 
m
 
 in Transiently Transfected HeLa Cells.
 
HeLa cells (5 
 
 
 
 10
 
5
 
) were transfected with the following previ-
ously described EGFP constructs: pEGFP-M11L, pEGFP-mt,
pEGFP-stop, and pEGFP-Bcl-2 (6). Respectively, these chimeric
proteins consist of an NH
 
2
 
-terminal EGFP tag appended with full
length M11L, the mitochondrial targeting sequence of M11L
alone, a nontargeted, truncated variant of M11L or full-length
Bcl-2. HeLa cells were transfected as described above and after 24 h,
were split into replicate wells and the cells were subjected to
apoptosis induction.
The first treatment involved incubation of cells with stauro-
sporine (Sigma-Aldrich) or staurosporine together with the PBR
ligand PK11195 (Sigma-Aldrich) for 4 h. Staurosporine and
PK11195 were used at concentrations of 5 and 120 
 
 
 
M, respec-
tively. Replicate cell samples were also individually treated with
staurosporine or PK11195 alone. All samples were adjusted to
contain the same amount of DMSO solvent and cells treated with
PK11195 alone served as controls. The second treatment in-
volved incubation of cells with another PBR ligand, protopor-
phyrin IX (PPIX; Sigma-Aldrich), at a final concentration of 25
or 30 
 
 
 
M for 2 h. Control cells were incubated with ethanol sol-
vent alone.
During the last half hour of both treatments, the orange fluo-
rescent compound, tetramethyl rhodamine, ethyl ester (TMRE;
Molecular Probes), was added to cells at a concentration of 0.2
 
 
 
M. TMRE is a mitochondrion-specific potentiometric dye that
displays increased uptake into mitochondria and increased fluo-
rescence intensity in proportion to increased 
 
  
 
m 
 
(53). Cells
were harvested by trypsinization, then EGFP and TMRE fluores-
cence were analyzed in live cells by flow cytometry using a Bec-
ton Dickinson FACSCalibur™ instrument equipped with an ar-
gon-ion laser with 15 mW of excitation at 488 nm. TMRE
fluorescence was collected with a 585/42 nm bandpass filter and
green EGFP fluorescence was measured using a 530/30 mn band
pass filter. A total of 10,000 cells were analyzed per sample with
fluorescence signals at logarithmic scale under conditions that
minimized bleed through. The percentage of EGFP-expressing
cells that were also TMRE positive was calculated for the gated
cell population in both control and treated cells. The reduction in
the percentage of dual positive cells after treatment was calculated
in each case and the results of three independent experiments
(
 
 
 
SD) are shown.
 
Measurement of 
 
  
 
m
 
 in Infected Jurkat Cells.
 
Jurkat or Jurkat-
PBR cells (5 
 
 
 
 10
 
5
 
) were mock-infected or infected at a MOI of
20 with either myxoma virus (vMyxlac) or the M11L knockout
virus (vMyxM11L
 
 
 
). 10 h after infection, cells were treated with
2 
 
 
 
M staurosporine dissolved in DMSO or an equivalent amount
of DMSO only. Alternatively, activating anti-Fas antibody (clone
CH11; Upstate Biotechnology) was added directly to the cell 
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culture medium at a concentration of 250 
 
 
 
g/
 
 
 
l. After incuba-
tion for 3 h, TMRE was added to cells at a concentration of 0.1
 
 
 
M and fluorescence was analyzed in live cells by flow cytometry
as before using a 585/42 nm bandpass filter. A total of 10,000
cells were analyzed per sample with fluorescence signals at loga-
rithmic scale. The reduction in the percentage of TMRE-posi-
tive cells in treated versus control cells was calculated for the
gated cell population. The results of three independent experi-
ments (
 
 
 
SD) are shown.
 
Results
 
M11L Physically Interacts with the Mitochondrial Permeability
Transition Pore.
 
Previous studies had shown that M11L is
antiapoptotic, localizes to mitochondria, and blocks 
 
  
 
m
 
loss in these organelles after apoptosis induction (6). We
therefore reasoned that this viral protein is likely to impact
the mitochondrial cell death control point, perhaps by di-
rect interaction with protein subunits of the permeability
transition pore. To investigate this possibility, M11L was
overexpressed in Cos-7 cells by infection with a vaccinia
virus expression vector (VVM11L). These cells, together
with cells infected with control vaccinia virus (VV601),
were radiolabeled with 
 
35
 
S methionine/cysteine for 12 h
and lysed by resuspension in hypotonic phosphate buffer
and dounce homogenization. Samples were divided into
duplicates and the hydrophobic cross-linker, DSS, was
added to one sample from each duplicate. In these studies,
the use of a hydrophobic cross-linker was found to be es-
sential for demonstrating M11L binding interactions, per-
haps because such interactions require the correct confor-
mation of proteins embedded in membranes. Monomeric
and complexed M11L was immunoprecipitated and ana-
lyzed by SDS-PAGE and autoradiography.
As shown in Fig. 1 A, M11L was only immunoprecipi-
tated from cells infected with the M11L-expressing
VVM11L vaccinia virus vector (lanes 1 and 3) and was not
detected in cells infected with control vaccinia virus
VV601 (lanes 2 and 4). In addition, when proteins were
cross-linked, a complex of 
 
 
 
36 kD was observed (lane 1)
and was not observed in the absence of cross-linking (lane
3). The presence of M11L in a 36 kD complex was veri-
fied using a similar approach involving infection of THP-1
and HeLa cells with VVM11L or VV601 followed by lysis,
cross-linking, immunoprecipitation, SDS-PAGE, and im-
munoblot analysis. As shown in Fig. 1 B, monomeric and
complexed M11L was detected in THP-1 and HeLa cells
infected with VVM11L (lanes 1 and 3) but was absent
from control VV601-infected cells (lanes 2 and 4). Forma-
tion of this cross-linked M11L complex was also observed
when experiments were conducted using Cos-7 and
HepG2 cells (unpublished data). The same procedure was
applied to BGMK cells infected with M11L-expressing
myxoma virus (vMyxlac) and the M11L knockout myx-
oma virus (vMyxM11L
 
 
 
). Monomeric and cross-linked
M11L was observed in cells infected with myxoma virus
but not the M11L knockout myxoma virus (Fig. 1 C, lanes
1 and 2).
Formation of a 36-kD complex suggested that the 18 kD
M11L protein associates with a protein of approximately
the same molecular weight. The PBR subunit of the PT
pore is 18 kD (23), and was therefore a candidate M11L-
interacting protein. To investigate whether M11L does in-
teract with the PBR, we conducted cross-linking experi-
ments as described above, using THP-1 monocytes because
these cells express a high concentration of the PBR (29).
THP-1 monocytes were infected with VVM11L or VV601
Figure 1. M11L can be cross-linked into a complex (A). Cos-7 cells
were infected with the M11L-expressing vaccinia virus VVM11L or the
control virus VV601 and labeled with 35S-methionine/cysteine. Proteins
present in hypotonic cell lysates were cross-linked with the hydrophobic
cross-linker DSS ( DSS) or left uncrosslinked ( DSS), before extraction
with an NP-40/deoxycholate buffer, immunoprecipitation with anti-
M11L antibody and analysis by SDS-PAGE and autoradiography. (B)
THP-1 and HeLa cells infected with VVM11L or VV601 were subjected
to hypotonic lysis and DSS cross-linking. M11L was immunoprecipitated
as described and detected by SDS-PAGE followed by immunoblot analy-
sis. (C) BGMK cells were infected with the vMyxlac parental myxoma
virus (Myx) or the M11L knockout strain vMyxM11L  (M11L ) and
again samples were subjected to hypotonic lysis, DSS cross-linking, and
immunoprecipitation and analysis of M11L. 
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and cross-linking was performed with DSP, the cleavable
analogue of DSS.
Fig. 2 shows the results following immunoprecipitation
of M11L (Fig. 2, A and B) or PBR (Fig. 2, C and D) from
lysates of THP-1 cells infected with VVM11L (lanes 1 and
2) or control VV601 (lanes 3 and 4). Samples shown in
lanes 1 to 4 were cross-linked before immunoprecipitation
and samples in lanes 2 and 4 were subjected to an addi-
tional treatment with reducing agents to cleave cross-
linked proteins. Control samples included were, in lane 5,
M11L immunoprecipitated from VVM11L-infected cells
in the absence of cross-linking and, in lane 6, a THP-1
whole cell lysate. M11L was detected in THP-1 cells in-
fected with VVM11L (Fig. 2 A, lanes 1 and 2) but not in
cells infected with VV601 (Fig. 2 A, lanes 3 and 4), as ex-
pected. The control samples also confirmed that M11L was
immunoprecipitated from VVM11L infected cells (Fig. 2
A, lane 5) and was not detected in the THP-1 whole cell
lysate (Fig. 2 A, lane 6), as expected. When the same blot
was probed with the anti-PBR antibody, PBR was found
to be present in samples immunoprecipitated with the
anti-M11L antibody (Fig. 2 B, lanes 1 and 2), indicating
that PBR coprecipitated with M11L. Monomeric PBR
was detected even in the absence of cross-linker cleavage
(Fig. 2 B, lane 1), indicating that non–cross-linked protein
also coimmunoprecipitated with M11L. A higher level of
 
PBR was identified in samples in which the cross-linker
had been cleaved before SDS-PAGE analysis (Fig. 2 B,
lane 2). PBR was also detected in the whole cell lysate, as
expected (Fig. 2 B, lane 6).
The reciprocal experiment, in which cross-linked PBR
was immunoprecipitated from THP-1 cells infected with
VVM11L and VV601 was also conducted. PBR was cor-
rectly detected in immunoprecipitates from infected THP-1
cells (Fig. 2 C, lanes 1–4) and in the THP-1 whole cell ly-
sate (Fig. 2 C, lane 6). PBR was not detected in a control
M11L immunoprecipitation in the absence of cross-linking
(Fig. 2 C, lane 5). When the same blot was analyzed using
an anti-M11L antibody, M11L was identified as having co-
precipitated with PBR in VVM11L-infected cells (Fig. 2
D, lane 2). As expected, M11L was also detected in a con-
trol M11L immunoprecipitate (Fig. 2 D, lane 5) and was
absent from samples infected with VV601 and from the
THP-1 whole cell lysate (Fig. 2 D, lanes 3, 4, and 6). We
conclude from these cross-linking experiments that M11L
interacts directly with the PBR.
 
FRET Analysis of the PBR-M11L Association.
 
To obtain
independent confirmation of a close association between
M11L and the PBR, FRET between a EYFP-M11L
chimeric protein and the PBR-binding fluorescent com-
pound FGIN-1–27-NBD was assessed. FRET is a process
whereby energy is transferred from a molecule (donor) to a
neighboring molecule (acceptor) nonradiatively through
dipolar–dipolar interactions (54, 55). FRET analysis there-
fore allows the detection of molecular interactions within a
Förster radiance distance (typically less than 10 nm). The
technology has been applied extensively for studying mo-
lecular interactions within cells (for reviews, see references
56 and 57). When FRET occurs, fluorescence quenching
of the donor is observed as a result of donor energy being
transferred to the acceptor. We used an acceptor pho-
tobleaching technique (51, 57) to investigate potential in-
teractions between FGIN-1–27-NBD (donor) and EYFP-
M11L (acceptor). The technique measures the emission of
donor molecules before and after selective photobleaching
of the acceptor. The increase, or dequenching, of the do-
nor emission is a direct measure of the FRET efficiency.
Fig. 3 shows one representative field of cells out of a to-
tal of 38 fields used in FRET analysis. Fig. 3 A shows a
HeLa cell monolayer stained with the PBR-specific fluo-
rescent compound FGIN-1–27-NBD and represented in
green pseudocolor. Fig. 3 B shows EYFP-M11L expres-
sion, represented in red pseudocolor, in the same mono-
layer. Fig. 3 C shows the unmixed signal using excitation
with the 458 nm laser line and Fig. 3 D is the bright field
image showing the cell morphology.
FRET was assessed in the cells shown in Fig. 3 C. The
cell outlined in red, emitting FGIN-1–27-NBD and
EYFP-M11L fluorescence and the cell outlined in green,
emitting FGIN-1–27-NBD fluorescence only, were pho-
tobleached (asterisk). The cell outlined in blue, emitting
FGIN-1–27-NBD and EYFP-M11L fluorescence and the
cell outlined in yellow, emitting FGIN-1–27-NBD fluo-
rescence only, were not photobleached. Fig. 3 E shows
Figure 2. M11L forms a complex with the PBR. THP-1 cells were in-
fected with VVM11L or VV601. Protein within hypotonic cell lysates
was cross-linked with DSP, extracted with an NP-40/deoxycholate
buffer, and immunoprecipitated with an anti-M11L (A and B) or anti-
PBR (C and D) antibody. Samples subjected to cross-linker cleavage ( )
or left uncleaved ( ) were analyzed by SDS-PAGE and immunoblotting
with either an anti-M11L (A and C) or anti-PBR (B and D) antibody.
M11L immunoprecipitated from cells infected with VVM11L in the ab-
sence of cross-linking or a THP-1 cell whole cell lysate (WCL) were in-
cluded as controls.  
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the intensity of the EYFP and FGIN-1–27-NBD fluores-
cence channels in the red-outlined cell and Fig. 3 F the
readings in both channels for the green-outlined cell. In
Fig. 3 E, after photobleaching of the EYFP-M11L accep-
tor fluorophore (arrow) an increase (dequenching) in the
emission of the donor (FGIN-1–27-NBD) fluorophore
was observed. In contrast, in a cell not expressing EYFP-
M11L (Fig. 3 F), photobleaching resulted in a decrease in
Figure 3. EYFP-M11L and fluorescently labeled
PBR undergo FRET (A). Confocal image of a repre-
sentative HeLa cell monolayer stained with FGIN-1–
27-NBD (shown in green pseudocolor) acquired using
a 548 nm excitation line and emission filter of 462–537
nm before photobleaching. (B) EYFP-M11L expression
in the same monolayer (shown in red pseudocolor) ac-
quired using a 515 nm excitation line and emission fil-
ter of 526–719 nm before photobleaching. (C) Un-
mixed signal obtained using a 458 nm laser line
excitation. The cells marked with an asterisk were pho-
tobleached. Regions of interest were drawn over the
cells to be analyzed. Here, regions designated by red
and green are a pair of photobleached cells and regions
designated by blue and yellow are an unbleached pair
of cells. All cells are stained with FGIN-1–27-NBD
and the cells designated by red and blue outlines ex-
press EYFP-M11L. (D) DIC image of the field of view
showing cell morphology. Scale bar: 10  m. (E) Inten-
sity of EYFP–expressing cell (red region in C) before
and after photobleaching. Notice the dequenching of
NBD signal after photobleaching (arrow). (F) Intensity
of the non-EYFP expressing cell (green in C) before
and after photobleaching (arrow). (G) Averaged nor-
malized intensity changes before and after photobleach-
ing in 38 fields of cells analyzed (standard error, P  
0.0000000233 and 0.0000000186 for time points 4 and
5 respectively). The y axis represents the intensity vari-
ation of the FGIN-1-27-NBD (donor) channel. The x
axis represents the sequence of time lapse points. Arrow
indicates the bleaching point.1134 Antiapoptotic, PT Pore-interacting Protein M11L
the NBD fluorescence. There was also a slight decrease in
the signal obtained in the EYFP channel that measured a
certain degree of background fluorescence. The averaged
dequenching in FGIN-1–27-NBD (donor) fluorescence in
38 pairs of cells is tabulated (Fig. 3 G) and a two-tailed
paired  t test was used to calculate the mean averaged
FRET of the two groups of cells. Dequenching was only
observed in EYFP-M11L–expressing cells after pho-
tobleaching. This phenomenon was not observed in any of
the controls analyzed (unpublished data).
All the pairs of EYFP-M11L–expressing cells analyzed
demonstrated a certain degree of FGIN-1–27-NBD de-
quenching. Given that there are difficulties in measuring
the FRET transfer efficiency in living cells due to the com-
plications of varied protein expression between cells and
possible incomplete photobleaching of acceptor molecules,
we calculated a FRET efficiency in the range of 2.8% to
78% (n   38) with an average value of 23.9%. No FRET
was observed in control experiments conducted using cells
that were stained with FGIN-1–27-NBD and expressed
EYFP alone (unpublished data).
M11L Acts at the Mitochondrial Cell Death Control Point
and Inhibits Cytochrome c Release. Translocation of cyto-
chrome c into the cytoplasm after induction of apoptosis
was evaluated in Rat2puro or Rat2M11L cells treated with
staurosporine for 2, 3, or 4 h. Supernatant fractions of digi-
tonin lysates were isolated and subjected to SDS-PAGE
and immunoblot analysis using an antibody specific for cy-
tochrome c. As shown in Fig. 4 A, whereas DMSO treat-
ment alone did not induce cytochrome c release from ei-
ther cell line (Fig. 4 A, lanes 1 and 5), staurosporine
treatment of Rat2puro cells triggered a rapid release of cy-
tochrome c into the supernatant fraction (Fig. 4 A, lanes
2–4). In contrast, after staurosporine treatment of Rat2M11L
cells, the release of cytochrome c was barely detectable,
even after 4 h (Fig. 4 A, lanes 6–8). Equivalent amounts of
protein were analyzed as shown by an anti-actin immuno-
blot (Fig. 4 A, bottom panel).
We wanted to determine whether M11L could prevent
cell death mediated by another apoptotic inducer that inter-
acts directly with the PT pore. PPIX is an endogenous
ligand of the PBR and is known to induce apoptosis in cell
lines (35) or when used as the active agent in photodynamic
therapy (47). Permeabilized Rat2puro and Rat2M11L cells
were treated with 20  M PPIX for 30 min at 37 C (Fig. 4
B). DMSO solvent alone did not induce cytochrome c re-
distribution (Fig. 4 B, top panel, lanes 1 and 3). However,
elevated levels of cytochrome c redistribution into the cyto-
solic fraction were observed in Rat2puro cells in compari-
son to Rat2M11L cells (Fig. 4 B, top panel, lanes 2 and 4)
whereas an anti-actin blot showed comparable protein load-
ing (Fig. 4 B, bottom panel). These results indicate that sta-
ble expression of M11L prevents cytochrome c translocation
into the cytoplasm in response to apoptotic stimuli. We
therefore conclude that M11L prevents apoptotic signals up-
stream of cytochrome c release and assists in the mainte-
nance of mitochondrial integrity.
M11L Functionally Modulates the Mitochondrial Apoptotic
Checkpoint. To explore the interaction of M11L with the
PBR in more detail, we chose to examine the ability of
transiently expressed M11L to counteract the proapoptotic
effects of PPIX as well as P11195, another PBR ligand that
directly targets the PT pore.
The ability of M11L to counteract   m loss induced by
PK11195 combined with staurosporine was assessed in HeLa
cells expressing recombinant proteins as EGFP fusion con-
structs for ease of detection. The following chimeric pro-
teins were expressed with an NH2-terminal EGFP tag: (a)
EGFP-stop incorporating a truncated variant of M11L that
lacks the mitochondrial targeting sequence, (b) EGFP-M11L
which incorporates full length M11L, (c) EGFP-mt which is
EGFP targeted to mitochondria by just the mitochondrial
targeting sequence of M11L, and (d) EGFP-Bcl-2 which in-
corporates full-length Bcl-2.   m in transfected cells was as-
sessed by measuring fluorescence of the potentiometric dye,
TMRE. At low concentrations, PK11195 is not proapop-
totic but this compound is known to amplify the effects of a
number of pro-apoptotic agents (42, 43). Indeed, treatment
of cells with PK11195 alone was found not to induce   m
Figure 4. Stable expression of M11L in Rat2 cells provides protection
against staurosporine- and PPIX-mediated cytochrome c release. (A)
Rat2puro and M11L-expressing Rat2M11L cells were treated with stau-
rosporine ( STS) or DMSO solvent alone ( STS) as control. Cyto-
chrome c redistribution into the cytosolic fraction of cell lysates was de-
tected by SDS-PAGE and immunoblot analysis (top panel). Equivalent
amounts of protein were analyzed as shown by the actin immunoblot
(bottom panel). (B) Treatment of permeabilized cells with 20  M PPIX
induced greater cytochrome c redistribution in Rat2puro cells than
Rat2M11L cells (top panel) when equivalent amounts of the cytosolic
fraction were loaded as assessed by actin content (bottom panel).1135 Everett et al.
loss or influence the proportion of EGFP-expressing cells
that were TMRE positive and these PK11195 treated cells
were used to calculate the maximum percentage of cells ex-
pressing EGFP constructs that were also TMRE positive.
After treatment, the percentage of EGFP-expressing cells
that were TMRE positive was also calculated and the reduc-
tion in the percentage of dual positive cells was calculated.
The results shown in Fig. 5 A reveal that HeLa cells ex-
pressing the negative control protein, EGFP-stop, were not
protected from   m loss after staurosporine treatment in
the absence or presence of PK11195. In marked contrast,
cells expressing EGFP-M11L were protected from both
treatments. EGFP targeted to mitochondria by the 25
amino acid M11L targeting sequence (EGFP-mt) was also
not protective. Cells transfected with EGFP-Bcl-2 were
protected from staurosporine-mediated apoptosis. How-
ever, in keeping with previous studies (43), the protective
properties of EGFP-Bcl-2, which are not thought to occur
by direct interaction with the PBR, were clearly coun-
teracted by the combined effects of staurosporine and
PK11195. From these results, we conclude that M11L is
effective in preventing   m loss in cells following stauro-
sporine treatment, even in the presence of the PBR ligand
PK11195. This ability to counteract the combined effects
of PK11195 and staurosporine distinguishes M11L func-
tionally from Bcl-2. These findings support the idea that
M11L is able to modulate the PT pore and that this might
occur via direct interaction with the PBR.
As with cells that stably express M11L, transiently ex-
pressed M11L was also protective against the effects of
PPIX. As shown in Fig. 5 B, in contrast to the negative
control EGFP-stop, EGFP-M11L was effective in prevent-
ing   m loss mediated by 25 or 30  M PPIX. EGFP-Bcl-2
was not at all protective against the concentrations of PPIX
used, in keeping with other studies (35). Unexpectedly, the
EGFP-mt construct, like EGFP-M11L, was able to prevent
  m loss after PPIX treatment, indicating a possible role for
the 25 amino acid mitochondrial targeting sequence of
M11L in interfering with PPIX binding to the PT pore.
M11L Binding to the PBR Is Biologically Relevant. To study
the biological importance of the physical association be-
tween M11L and the PBR, we investigated the ability of
myxoma virus infection to protect cells from staurosporine-
mediated apoptosis in the context of different PBR expres-
sion levels. PBR-deficient Jurkat T lymphocytes or PBR
overexpressing Jurkat-PBR cells were infected with the
myxoma virus, vMyxlac, to allow the expression of M11L.
For control purposes, parallel samples from both cell lines
were mock-infected or infected with a M11L-knockout
myxoma virus (vMyxM11L ). Cells were treated with 2
 M staurosporine or DMSO solvent as a control and
TMRE fluorescence was used to measure   m loss. As
shown in Fig. 6 A, a marked loss of TMRE fluorescence
occurred after staurosporine treatment of both Jurkat and
Jurkat-PBR cells that had been mock infected, with the
presence of PBR only providing a slight protective effect.
Myxoma virus infection was found to protect both cell
lines from staurosporine-induced   m loss. However,
vMyxlac infection of Jurkat-PBR cells provided a level of
protection against   m loss that was twofold greater than
the protection afforded control Jurkat cells. Infection of
both cell lines with the M11L-deficient vMyxM11L  did
not provide protection against staurosporine-induced   m
loss. Similarly, when apoptosis was induced by Fas stimula-
tion the same trends could be observed (Fig. 6 B).
For control purposes, virus infection was monitored in
Jurkat and Jurkat-PBR cells (Fig. 6 C). Mock-infected as
well as vMyxlac- and vMyxM11L -infected cells were an-
alyzed for the presence of M11L and another viral early
protein, M-T7 (58). Immunoblot analysis of immunopre-
cipitated M11L revealed that, as expected, M11L was not
present in mock-infected cells or cells infected with the
knockout virus (Fig. 6 C, top panel, lanes 1, 3, 4, and 6),
but was only present in vMyxlac-infected cells (Fig. 6 C,
lanes 2 and 5). M-T7 was not detected in mock-infected
cells (Fig. 6 C, bottom panel, lanes 1 and 4) and levels of
Figure 5. The mitochondrial targeting of M11L is important for inhi-
bition of   m loss induced by the PBR ligands PK11195 and PPIX. (A)
Cells expressing EGFP appended with truncated, nontargeted M11L
(stop), full length M11L, the mitochondrial targeting sequence (mt), or
Bcl-2 were treated with 5  M staurosporine (STS) or 5  M staurospo-
rine in combination with 120  M PK11195 (STS PK1195). The reduc-
tion in the percentage of TMRE-positive EGFP-expressing cells after
treatment is shown. The data represent the average of three independent
experiments ( SD). (B) Cells expressing EGFP chimeras were treated
with 25 or 30  M PPIX. The reduction in the percentage of TMRE
positive EGFP-expressing cells after treatment is shown. The results rep-
resent the average of three independent experiments ( SD).1136 Antiapoptotic, PT Pore-interacting Protein M11L
M-T7 in lysates of Jurkat and Jurkat-PBR cells infected
with vMyxlac and vMyxM11L  viruses were comparable
(Fig. 6 C, bottom panel, lanes 2, 3, 5, and 6), indicating
that production of early viral proteins was uniform.
Discussion
We have shown previously that M11L is antiapoptotic,
localizes to mitochondria, and prevents the loss of mito-
chondrial inner membrane potential in response to induc-
tion of apoptosis (6). M11L is a novel protein and cur-
rently has no database homologues outside the poxvirus
family (49). However, it is interesting that M11L, like the
antiapoptotic Bcl-2 proteins, prevents mitochondrial am-
plification of apoptotic signals (6). The mechanistic details
underlying the functions of Bcl-2 family members are un-
clear, but it has been proposed that they exert their modu-
latory effects by direct physical association with the PT
pore. In support of this model, Bcl-2 proteins including
Bcl-2, Bcl-XL, and Bax have been shown to physically in-
teract with both the ANT and VDAC subunits of the PT
pore (12, 14). In addition, another novel viral antiapop-
totic protein, vMIA of cytomegalovirus, interacts with the
ANT and acts to prevent apoptotic changes downstream
of mitochondria (17).
In the current study we have shown, using two indepen-
dent approaches, that M11L physically associates with the
PBR. Specifically, M11L and PBR could be cross-linked
into a complex and, in addition, FRET analysis demon-
strated a close association between a EYFP-M11L chimera
and the PBR-specific fluorescent compound FGIN-1–27-
NBD. This represents, to our knowledge, the first evidence
that the PBR may physically associate with an antiapop-
totic protein able to modulate mitochondrial function. We
have also shown that, when expressed in a stable cell line,
M11L inhibits cytochrome c release induced by staurospo-
rine and by the PBR ligand, PPIX, therefore indicating
that M11L functionally prevents transmission of apoptotic
signals that proceed via mitochondria.
Transiently expressed M11L was also characterized with
respect to its ability to counteract   m loss induced by
PPIX as well as by the PBR ligand, PK11195, that is
known to potentiate the action of several proapoptotic
agents. Both of these ligands are able to bind PBR in
the outer mitochondrial membrane and in the case of
PK11195, this occurs independently of VDAC (59). M11L
was found to effectively counteract   m loss triggered
by staurosporine, staurosporine in combination with
PK11195, as well as by PPIX.
Transient expression of the nontargeted M11L trunca-
tion mutant failed to protect cells from apoptosis. This par-
allels observations made with Bcl-2. Bcl-2 is targeted to
membranes of the endoplasmic reticulum, outer mitochon-
drial membrane and perinuclear membrane by means of a
COOH-terminal signal-anchor sequence (60) and requires
membrane association in order to function (61, 62). Bcl-2
constructs specifically targeted by heterologous targeting
signals to either mitochondria or the endoplasmic reticu-
lum both possess antiapoptotic activities in discrete systems
(63, 64). The current study therefore reinforces the com-
mon requirement of membrane association in order for
M11L and Bcl-2 to prevent apoptosis.
Differences in M11L and Bcl-2 function were also ob-
served. M11L displayed greater protective properties than
Bcl-2. This may reflect a situation in which M11L, a viral
protein, intrinsically has more potent antiapoptotic proper-
ties than Bcl-2 or may reflect the cell death–sensitizing ef-
fects resulting from Bcl-2 overexpression, both these phe-
nomena having been reported previously (65). Also, in
Figure 6. PBR expression augments the protective effects of myxoma
virus infection. Jurkat or Jurkat-PBR cells were mock-infected (mock) or
infected with myxoma virus (Myx) or the M11L knockout virus
(M11L ). The percentage of cells that underwent a loss of TMRE fluo-
rescence as a result of staurosporine treatment (A) or Fas stimulation (B) is
shown. Results are the average of three independent experiments ( SD).
In parallel, Jurkat or Jurkat-PBR cells that had been mock- or virus-
infected were analyzed for the presence of M11L using immunoprecipita-
tion and immunoblotting (C, top panel). Alternatively, virus infection
was verified by the production of the early viral protein, M-T7 (C,
bottom panel).1137 Everett et al.
keeping with previous studies, Bcl-2 did not protect cells
from PK11195 in combination with staurosporine or high
concentrations of PPIX (35, 43). In contrast, M11L was
protective under these conditions. Bcl-2 has been reported
to interact physically with the VDAC and ANT compo-
nents of the PT pore, but is not thought to bind directly to
the PBR. The ability of PK11195 or PPIX to overcome
the antiapoptotic effects of Bcl-2 can be rationalized if
binding of either ligand to the PBR perturbs the entire
pore structure and prevents Bcl-2 from binding the other
subunits, an effect that would only be evident when an-
other apoptotic stimulus is applied. The observed differ-
ences in the properties of M11L and Bcl-2 supports the
idea that M11L directly counteracts the proapoptotic ef-
fects of PBR ligands by inhibiting their binding to the
PBR or by stabilizing the PBR within the pore structure.
Another interesting observation was that the hydropho-
bic mitochondrial targeting sequence, mt, might itself
possess antiapoptotic activity, particularly against PPIX,
although it was not effective against PK11195 and stauro-
sporine. This may relate to the fact that PK11195 and
PPIX have different binding sites on the PBR as revealed
by binding inhibition studies conducted with an antibody
directed against an epitope in the extreme COOH-termi-
nal region of PBR which is orientated toward the cyto-
plasm (29). Specifically, this antibody was able to block
PK11195 but not PPIX binding, indicating that PK11195,
but not PPIX, binds the COOH-terminal, cytoplasmic
domain of PBR. Our data suggests that the hydrophobic
targeting signal of M11L may interact with PBR in a re-
gion overlapping the PPIX binding site. In contrast, the
full-length M11L protein may be required to prevent
binding of PK11195 to the cytoplasmic COOH-terminal
region of PBR.
We showed previously that myxoma virus infection of
the RL-5 rabbit lymphocyte cell line provides protection
against staurosporine-mediated apoptosis (6). Interestingly,
we found in this study that infection of Jurkat cells with
myxoma virus, but not the M11L knockout virus, pro-
tected these cells from   m loss induced by staurosporine
and by Fas activation. This protective effect was accentu-
ated in the presence of elevated levels of PBR. This implies
that the physical association of M11L and the PBR is im-
portant in infected cells. However, M11L, like Bcl-2,
probably has multiple binding interactions that contribute
to its antiapoptotic properties.
The ability of M11L to bind to the PBR is intriguing in
another context. The PBR is thought to potentiate inflam-
matory responses, an effect counteracted by the PBR
ligand PK11195 (31, 32). We have observed that, during
myxoma virus infection, absence of M11L paradoxically
results in increased levels of both apoptosis and inflamma-
tion (6) implying that, in the infected rabbit, M11L has
both antiapoptotic and antiinflammatory roles. We pro-
vided a potential explanation for this finding by showing
that M11L function is particularly important during infec-
tion of monocytes (6). Prevention of monocyte apoptosis
during infection has important consequences because,
when cells of this lineage undergo apoptosis, they also pro-
mote inflammation (6, 66). Within hematopoeitic lineages,
PBR is present in highest concentration in monocytes
(28), raising the possibility that M11L interaction with the
PBR contributes to the observed anti-inflammatory effects
of M11L.
In conclusion, we have shown that M11L, an important
virulence factor produced by myxoma virus, blocks apop-
totic signals that proceed via the mitochondrial cell death
control point. M11L binds to and functionally modulates
the PBR component of the PT pore. Identification of cer-
tain functional similarities between M11L and Bcl-2 also
raises the possibility that M11L, like Bcl-2, has multiple
functions and binding partners. Investigation of M11L con-
tinues to provide valuable insights into how an antiapop-
totic protein contributes to virus virulence and also into
fundamental aspects of cell death pathways themselves.
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